Q1 2022 Results
Company overview
Financial performance
CRM
Financial review
Immunology
Neuroscience
2022 priorities
Appendix
References
Innovation: Pipeline overview
Innovation: Clinical trials
Abbreviations
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
iscalimab - CD40 inhibitor
Study
Indication
Phase
NCT03781414 CONTRAIL I (CCFZ533A2202)
Liver transplantation
Phase 2
Patients
128
NCT03905525 TWINSS (CCFZ533B2201)
Sjögren's syndrome
Phase 2
260
Primary Outcome
Measures
Arms Intervention
Proportion of patients with composite event (BPAR, Graft Loss or Death) over 12
months
Control/Standard of Care: TAC + MMF + Corticosteroids
CFZ533 dose A+ MMF + Corticosteroids
CFZ533 dose B + MMF + Corticosteroids
Liver transplant recipients
Change in EULAR Sjögren's syndrome Disease Activity Index (ESSDAI) score and
EULAR Sjögren's syndrome Patient Reported Index (ESSPRI) score
Three dose arms of CFZ533
Placebo
Target Patients
Read-out Milestone(s)
2023
Publication
2023
Patients with Sjögren's syndrome
2022
2022
64 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation